UK life sciences trade group calls for oral Covid-19 antiviral investment
The UK government must invest in Covid-19 antiviral treatments like it did with vaccines, said the chair of the UK…
By
Respiratory
Latest in
Respiratory
NRx seeks breakthrough therapy designation for Covid-19 treatment
In a randomised trial, the therapy demonstrated a statistically significant two-fold increased odds of survival.
By
FDA approves AstraZeneca-Amgen’s Tezspire for severe asthma treatment
The approval is based on data from the PATHFINDER trial programme and Phase III NAVIGATOR trial of the antibody.
Covid-19: Pfizer’s antiviral Paxlovid effective against severe disease and Omicron variant
Analysis of the Phase II/III trial for Paxlovid found it reduced the risk of hospitalisation or death by almost 90%.
By
Covid-19: GSK’s sotrovimab retains activity against Omicron variant
Companies like GSK are racing to prove efficacy of their monoclonal antibodies against the new SARS-CoV-2 variant Omicron.
By
Molnupiravir: Merck’s Covid-19 antiviral less effective in new analysis
Updated data on molnupiravir shows the drug reduces hospitalisation or death by 30%, down from the initially reported 50% efficacy.
By
Paxlovid: what we know about Pfizer’s Covid-19 pill
Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid.
By
Q&A: Covid-19’s Delta subvariant and the risky winter ahead
Virologist Dr Phillip Gould discusses the Delta subvariant, vaccines, and the new Covid-19 antiviral molnupiravir.
By